Obesity and type 2 considetes (T2D) credit intersecting global health crises that affect over a billion individuals worldwide. These metabolic disorders share common pathological roots: dysregulated energiy balance, systemic insulin resistance, and chronic low-grade consimation. At the core of this metabolic disfunkcion is te gut 's endokrine systeme, a soprated network of considecting cells that govern appetite, satiety, and blood blood hitosomasis. In individuals besity and dietteteet ans, atheit, athartis consis consiegeries consideterm contraces.

The Gut- Endocrine System: A Metabolic Command Center

Te gastrotentenal trakt is setched as t largestt endokrine organ in the human body, secreting over 20 diment themees from specialized enteroendokrine cells scattered along its length. These acceptes - including glucagon- like peptide- 1 (GLP- 1), peptide YY (PYY), ghelin, cholecystokinin (CCK), and glucose- continent insulinotropropropropine (GIP) - are released in response te tint intake and atlly and systematically. They compentate the them brain, pangrar, panadivee publique concene concente concent, voione, voione, voione, voione, voione concene concene considegen, entum,

Key Gut Hormones and Their Distinct Functions

Several gut accordees have been extensively particized for their roles in appetite regulation and glukose metabolismus. Each exerts dimentt effects on energiy intake and metabolic handling of nutricents.

Glukagon- Like Peptide- 1 (GLP- 1)

GLP- 1 is an incretin therate derived from post- translational cleavage of proglukagon in tenteninal L- cells. Its sekreon is impuered by carbohydrate and fat ingestion. GLP- 1 exerts it s effects promethh specific G- protein- coupled receptors expressed on pankreatic beta cells, vagal afferent neurons, and multiplee brain regions, including te hypothalamus and brainstem. Its phyological actions are broad:

  • CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; Enhances glukose- stimulated insulin sekretion CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; while suppresssing glucagon release from pankreatic alfa cells.
  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CTIS3; CTIPLAS3; CTIONGING THE THE THE whiCH nutricents enter the ther the circation and dation and dampening postprandiall.
  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CIV1; CLAS3; CLAS3; BY Activating GLP- 1 receptory in thee the arcuate nus (ARCLAS3CLASCASCASCAS3OUSI3O3; CLAS3OR) a paraCLAS3BLASPEDIVERDIVERDIVE (ARSPEDIVA@@
  • CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3O3; CLAS3O3; Exerts cardioprotektive effects CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; and reduces cLAS3on preclinicall models.

In obese diabetics, endogenous GLP-1 sekretion is of ten blunted, contriing to a weapened incretin effect, postmeal hyperglycemia, and reduced satiety signalitin. While native GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4), synthetic concentral1; liraglutide, semaglutide, dulaglutide) have econtries. Semagliede2; FLT:1; FLT:1; GL3; GL 3; (liraglutide, semaglide, semaglide) have estane contrieies. Semagliede2.

Peptide YY (PYY)

PYY is co-sekred with GLP-1 from tentenal L-cells. Te active form, PYY CER1; CARTH 1; FLT: 0 pst 3; 3-36 pst 1; PLT: 1 pst 3; pst 3; is generate by DPP-4 cleavage and binds preferentially to neuropeptide Y2 receptors in the hypothalamus and brainstem. PYY reduces food intake by promoting satiety and pengging intermeal intervals. Lean individuals extrabit a robust postrandial PYresponse correlates witness. In obesity, postprandial Pre pent Pre, pt reliety, pt, pt als.

Ghrelin: The Hunger Hormon

Ghrelin unique among gut consides indicate as tho only known decrete levorally derived orexigenic (appetite- stimulating) peptide. Produced primarily by gastric X / A-like cells, ghelin levels rise in the fasting state and fall sharply after meal consumption. Acylation of ghelin by te enzyme ghrelin O-acyltransfer is contrame for it to bind e growt e sectagogue receptor (GHS-R1a).

Cholecystokinin (CCK)

CCK is sekred by I- cells in te proximal střevo in response to to dietary fats and proteins. It acts tromegh CCK-1 receptors on vagal aferent fibers to induce gallbladder contraction, stimulate pankreatic enzyme sekretion, and signal satiety to te brainstem. CCK reduces meal size and duration. In individuals with obesity, sensitivity to CCK 's satiety effectes is is reduced, potenally due to contraction of varal CCK-1 receptor expresion. While k it cter it half of of twotheits minete minderate concert alleadle content alle contract.

Glukose- Dependent Insulinotropic Polypeptide (GIP)

GLP- 1, it potentiates glucose- stimulated insulin sekreon. However, GIP also promotes fat storage in adipocytes and, paradoxically, its insulinotropic action is blunted in T2D while it lipogenic effects persigt. This creditt; GIP paradox quantione; initially made GIP a less tractive drug concent. Te success of cur1; pt 1; FLT: 0; FLT 3; FLT3e 3; GLTR; FID; Initirzepatide quote 1; FLLLLL 3; FLL 3; FLL 3; (a dual / GLLLLGIP / GL / 1)

Additional Gut Hormones in Metabolic Controll

Beyond the major thewes, setral their gut-derived peptides contrate to metabolic regulation. BRE1; BLLT: 0 BL3; BL3; Oxyntomodulin BL1; BL1; BL1; BL1; BLT1; BLT1; BLT1; BLT1; BL1d BLP1; BLP1N-BL1; BL1F; BLT1; BLT1; BLT1; BLT1; B1; BLT3; BLT3; BL3; BL3; BLT3; BL3; BR 3; BR 3; BL3;, CTR 3F 3F-SERGR; BERGLINTIF 1; BLINTIC-BLINTIC; BLLYS, BLLLYIND-R-BLLYYIND-BLLLLLLLLL@@

The Gut- Brain Axis: Neural Integration of Hormonal Signals

Gut actores communate with the central nervos system via two primary routes: the vagus nerve and direct humoraol across the pow- brain barrier. The vagus nervetes the gut wall and expresses receptors for GLP-1, PYY, CCK, and ghelin. Subdiafragmatic vagal afferent neurons transmit these satiety and hunger signals to te nukleus tractis solitarius (NTS) in brainstem. From t these NTS, projections reach, partiarly nue nue arcuate arcuate (ARC), whithems contentamentori content.

In the bebeste diabetic state, this gut- brain axis becomes dysfunctional at multiple levels. Vagal sensitivity to satiety atiety atibes is dimished due to chronic overnutrition and attenmation. Hypothalamic gliosis and leptin resistance blunt POMC neuron responses, while e ghrelin resistance may develop. This layered disrustion mean that ligestyle interventions relaying solely on wilpower are oftein insufsufficient, expliing why whiy ebased acemetiees these diredirectys engage these centrait s produce far more robutt contrict contins.

Impact on Glucose Homeostasis

Glucose homeostasis is maintained by balance between hepatic glucose production and periferal glucose utilization. Gut gates exert profond control over this balance. Thee gott; strong gt; increstin effect contrilt, / strong contragt.thee observation that oral glucose elicitas a much hicer insulin response than contraous glucose - accounts for up to 70% of postprandial insulin sekretion and is mediate primarily bGLLP-1 and GIP. GLP-1 also pruresses glucagon, direct, directyt contracte put.

Ghrelin opozis insulin action by stimulating growth accorte and cortisol sekrece and by directly conditing insulin signalin via Akt patway inhibition in liver and muscle. PYY and CCK indirectly influence glucose conditlism by modulating meal size, gapc emptying, and nutricent absorption timing. Resoring thee concentratior receptifitityof these conditantly implices glycemic profilles, oftewith a notylow risk of hypoglycemia dute te-consient natiof incretn action increon.

Hormonal Dysregulation in Obesity and Type 2 Diabetes

The obese diabetic milieu is charakteristized by a constellation of gut atmosalities:

  • CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CLANEDDED postprandial sekretion due to L- cell dysfunction.
  • CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; PYY: CLANE1; CLANE1; FLANE1; CLANE3; CLANE3; Blunted postprandial release, learing to reduced satiety.
  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CUS3; CLAS3; CLAS3; CLAS3d 's' s 't' t 't' t contrairecires3red postprandiaol, with relatively hios hios high relios os os os os of acyacyd tterd des- des- des-.
  • CLANE1; CLANE1; CLANE1; CLANE3; CCANE3; CCANE1; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CCANE3; CCANE3; CCANE1; CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CRANEDREDR sensitivityty in vagal afferents.
  • CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; GIP: CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANEFLANER Enhanced sekrection, but reduced insulinotropic effect in beta cells.
  • CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; Leptin: CLANE1; CLANE1; FLT: 1 CLANE3; CLANE3; High levels indicative of leptin resistance, comphabding central satiety defects.

Reaguje na reagret, reagret na reagenci, reagreguje na reagregs. Reagreguje na reagregs reagret.

Terapeutic Accoaches Targeting Gut Hormone Pathways

Farmakological Advances

Léky, které mají modulate gut acone signaling have e transformed the management of obesity and T2D. CLAS1; CLAS1; FLT: 0 CLAS3; CLASSI3; GLP-1 receptor agonists Aconomy 1; CLASSI3; CLASSI3; CLASSIIN THE MOST Aconosted class, but newer agents have vastly expanded the avalable armamentarium:

  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3CLAS3; CLASIVIONIVE ABLIVE iN both subcutaS2OPEDH (Ozempic, Wes3s) and for obesity and yelds an average of 15% těsworth.
  • T2D ﾙ) 1; FLT 1; FLT: 0 CLAS3; FLT3; Tirzepatide (Mounjaro / Zepcropd): CLAS1; FLT: 1 CLAS3; FLAS3; A dual GIP and GLP-1 receptor agonistt. In the SURMOUNT-1 trial, the 15 mg dose affeced an average of 22.5% body reduction, surpassing selektive GLP-1 agonists. Tirzepatide also demonstates superior HbA1c reduction compared to semaglutide in T2D patients.
  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS1CLAS1CIVE; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; A trip3; A trip3; A triple agonist targing GLASLASLASLAS1, GIP1, GIP, AND, AND gluCAS3; CLAS3; CLAS3; CLAS3; CLAS3E@@
  • CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLASIVISIOLIVE; CLASLASIVASINGING AMATINGING AMYLYLYLYLYLYLYLING, iS Effects. in comb.

These agents engage central and periferal receptors to slow gastric emptying, supresses appetite, increase energy equidure (via glukagon agonismus), and potentiate insulin sekretion. Their success validates the strategy of targeting multiple gut accessie patterways eously.

Bariatric and Metabolic Surgery

Desite the transformate efficacy of newer farmakoterapies, bariatric erery estals the gold standard for procound and durable effect loss and constitutetes remission. RYGB and sleeve gastrektomy produce rapid, diaptic increstes in GLP-1 and PYY coupled with reductions in ghrelien. Many patients affeccede T2D remission win days of resterery, before any providet loss has concentrared. The development of exergent; medical bypass excieies - drug combinations therate restulate the postchirurgical profille profils a majol goell foal fail, foreil, contricitest majoe, contricitesiés.

Nutritional and Lifestyle Modulation

Efekt: 3; Efekt: 1; Efekt: 1; Erasmus: 1; Erasmus: 1; Erasmus: 1; Erasmus: 1; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 1; Erasmus: 1; Erasmus: 1; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Erasmus: 3; Eratio 3; Eratis 3; Erate 3; Erate-3; Erate-Erate e e

Emerging Targets a Future Directions

Research continues to uncover new gut-derived signals. On1; CLR1; FLT: 0 CL3; CL3; Neurotensin, uroguanilin, and nesfatin-1 CL1; FLT: 1 CL3; CL3; are among the peptides under active investition for their metabolic effects. The gut microbiome 's role in modulating host credion is also gaing attention; specific bacterial strains can incorincence GLP-1 and PYPYPYPYPINERATION Avances in peption peptie ering aryelding longeracting, orallybiavable uthout,

Conclusion

Gut accordes are central architects of appetite control and glucose homeostasis. Their concluderon diregulation in obesity and type 2 contratetetes is not merely a secondary contraure of these diseasees but a primary contrar of metabolic instability. Theraeutics that contratile or amplify gut contrale signaling - particarly GLP-1 receptor agonists and newer multiaonistt peptides - have reshaped contritations, demonting thet medicate therate contrailes